Inclusion Criteria:

          -  Participants must fulfill all of the following criteria to be eligible for the study
             at the time of tumor resection and initiation of TIL expansion.

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Participants must have metastatic, high-grade soft tissue sarcoma, all subtypes will
             be eligible

          -  Residual measurable disease after resection of target lesion(s) for TIL growth

          -  Eastern Cooperative Oncology Group (ECOG) 0 to 1. ECOG performance status of 0 to 1
             will be inferred if the patient's level of energy is ≥ 50% of baseline.

          -  Participants must have progressed on at least one prior standard of care treatment
             regimen for metastatic disease.

          -  A negative pregnancy test (urine or serum) must be documented at screening for women
             of childbearing potential.

          -  A MUGA scan (ejection fraction > 50% is required) ≤ 6 months prior to lymphodepletion.

          -  Pulmonary function tests should be completed ≤ 6 months prior to lymphodepletion and
             forced expiratory volume (FEV1) > 65% or FVC > 65% of predicted are required

          -  Adequate renal, hepatic, and hematologic function, including creatinine of ≤ 1.7
             gm/dL, total bilirubin ≤ 2.0 mg/dL, except in patients with Gilbert's Syndrome who
             must have a total bilirubin less than 3.0 mg/dL, AST and ALT of less than 3 X
             institutional upper limit of normal, hemoglobin of 8 gm/dL or more, white blood cells
             of 3000 per mm^3 and total granulocytes of 1000 per mm^3 or more, and platelets of 100
             000 per mm^3 or more.

          -  Participants must have a positive screening EBV antibody titre on screening test.

          -  Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the
             participant agrees to continue to use a method of contraception throughout the study
             such as: barrier (i.e. condom, diaphragm), hormonal, IUD, or sponge plus spermicide.

          -  Prothrombin time (PT) and partial thromboplastin time (PTT) within 1.5 times the
             institutional upper limit of normal

          -  Participants with echocardiogram (EKG) within 14 days of initiation of chemotherapy
             demonstrating no new rhythm, axis, or ST segment

          -  Urinalysis within 14 days demonstrating no evidence of a urinary tract infection.

        Exclusion Criteria:

          -  Participants with active systemic infections requiring intravenous antibiotics,
             coagulation disorders, or other major medical illnesses of the cardiovascular,
             respiratory, or immune system are excluded.

          -  Participants testing positive for HIV titer, hepatitis B surface antigen, human T-cell
             leukemia-lymphoma virus (HTLV) I or II antibody, or both rapid plasma regain (RPR) and
             fluorescent treponemal antibody (FTA) are excluded. Participants with hepatitis C
             antibody must have a negative (undetectable) viral load by polymerase chain reaction
             (PCR).

          -  Participants who are pregnant or nursing are excluded.

          -  Participants needing chronic immunosuppressive systemic steroids are excluded

          -  Participants with autoimmune diseases that require immunosuppressive medications are
             excluded

          -  Presence of a significant psychiatric disease, which in the opinion of the principal
             investigator or his designee, would prevent adequate informed consent or render
             immunotherapy unsafe or contraindicated

          -  Participants with central nervous system metastases will be excluded.

          -  Inability to comprehend and give informed consent